Study details
Enrolling now
RA-PRO PRAGMATIC TRIAL
University of Alabama at Birmingham
NCT IDNCT04692493ClinicalTrials.gov data as of Apr 2026
Phase
Phase 3
Target enrollment
924
Study length
about 7.3 years
Ages
18+
Locations
48 sites in AL, AZ, CA +15
What this study is about
Researchers are testing whether switching to a non-TNFi biologic or a targeted synthetic DMARD (tsDMARD) improves patient-reported outcomes in people with active rheumatoid arthritis who are already taking a TNFi-biologic. The trial will compare these two treatment options to each other and to continuing the current TNFi-biologic treatment.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take non-TNFi-biologic class
- 2.Take targeted synthetic DMARD class
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized (Open Label)
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Body systems
Immune